{"id":3889,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/daclizumab-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"daclizumab-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/daclizumab-txt\/","title":{"rendered":"Daclizumab.txt"},"content":{"rendered":"

Daclizumab<\/h1>\n

CLINICAL USE <\/H3>
\nHumanised murine\/human monoclonal anti-CD25 antibody:Prophylaxis of acute allograft rejection, in combination with maintenance immunosuppressants

DOSE IN NORMAL RENAL FUNCTION <\/H3>1 mg\/kg within 24 hours of transplantation, then 1 mg\/kg every 14 days for 5 doses. See \u2018Other Information\u2019

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :144 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : No data<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :5.3 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :270\u2013919\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>Over 15 minutes

    Comments<\/H4>Add required dose to 50 mL of sodium chloride 0.9%Stable for 24 hours at 2\u20138\u00b0C if prepared aseptically

    OTHER INFORMATION <\/H4>An alternative dosing regimen that may be used is 2 mg\/kg every 14 days for 2 doses
    \n","protected":false},"excerpt":{"rendered":"

    Daclizumab CLINICAL USE Humanised murine\/human monoclonal anti-CD25 antibody:Prophylaxis of acute<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3889","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3889"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3889\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}